TG Therapeutics, Inc.
TGTX
$29.45
$0.6752.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 309.75% | 147.26% | 261.84% | -96.59% | 114.45% |
| Total Depreciation and Amortization | -31.58% | -72.41% | -76.32% | -84.93% | -40.63% |
| Total Amortization of Deferred Charges | -49.42% | -49.13% | -48.55% | -32.51% | 0.00% |
| Total Other Non-Cash Items | 81.48% | 83.61% | 33.73% | 67.38% | -34.05% |
| Change in Net Operating Assets | -244.50% | -700.08% | -654.44% | 20.65% | -30.44% |
| Cash from Operations | 34.32% | -249.88% | -94.10% | -114.58% | 113.18% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -323.80% | -39.48% | 135.32% | 69.20% | -94.21% |
| Cash from Investing | -326.18% | -39.75% | 135.28% | 69.12% | -94.21% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 220.00% | 110.00% | -- | -52.73% | -99.71% |
| Repurchase of Common Stock | -- | -- | -661,000.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -4,872.59% | -61,120.00% | -607,100.00% | 31,836.82% | -99.71% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -140.33% | -173.61% | 72.53% | 109.51% | -79.08% |